{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '6.2.7.', '78']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '7.', 'ASSESSMENT OF SAFETY', 'In this study, safety will be assessed by qualified study personnel by evaluating the following:', 'reported adverse events, clinical laboratory test results, vital signs measurements, ECG findings,', 'physical examination findings (including body weight and height measurements), use of', 'concomitant medication, neurological examination, C-SSRS, and CDI-2.', '7.1.', 'Adverse Events', '7.1.1.', 'Definition of an Adverse Event', 'Any untoward medical occurrence in a patient or clinical investigation subject administered a', 'pharmaceutical product and which does not necessarily have to have a causal relationship with', 'this treatment.', 'An adverse event can, therefore, be any unfavorable and unintended physical sign, symptom, or', 'laboratory parameter that develops or worsens in severity during the course of this study, or', 'significant worsening of the disease under study or of any concurrent disease, whether or not', 'considered related to the IMP (TEV-50717). A new condition or the worsening of a pre-existing', 'condition will be considered an adverse event. Stable chronic conditions (such as arthritis) that', 'are present before study entry and do not worsen during this study will not be considered adverse', 'events.', 'Accordingly, an adverse event can include any of the following:', 'intercurrent illnesses', 'physical injuries', 'events possibly related to concomitant medication', 'significant worsening (change in nature, severity, or frequency) of the disease under', 'study or other pre-existing conditions (Note: A condition recorded as pre-existing that', 'is intermittently symptomatic [eg, headache and that occurs during this study should', 'be recorded as an adverse event.)', 'drug interactions', 'events occurring during diagnostic procedures or during the washout phase of this', 'study', 'laboratory or diagnostic test abnormalities that result in the withdrawal of the patient', 'from the study, are associated with clinical signs and symptoms or a serious adverse', 'event, or require medical treatment or further diagnostic work-up, or are considered', 'by the investigator to be clinically significant (Note: Abnormal laboratory test results', 'at the screening visit that preclude a patient from entering the study or receiving study', 'treatment are not considered adverse events.)', '79']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '7.1.2.', 'Recording and Reporting Adverse Events', 'For recording of adverse events, the study period is defined for each patient as that time period', 'from signature of the informed consent/assent form to the end of the follow-up period. For this', 'study, the follow-up period for recording of adverse events is defined as 1 week of washout for', 'patients who will participate in the open-label safety extension study TV50717-CNS-30047 and', '2 weeks after the last dose of IMP for patients who will not roll over into Study TV50717-CNS-', '30047.', 'All adverse events that occur during the defined study period must be recorded both on the', 'source documentation and the CRF, regardless of the severity of the event or judged relationship', 'to the IMP. For serious adverse events, the Serious Adverse Event Form must be completed, and', 'the serious adverse event must be reported immediately (see Section 7.1.5.3.1). The investigator', 'does not need to actively monitor patients for adverse events after the defined period. Serious', 'adverse events occurring to a patient after the treatment of that patient has ended should be', 'reported to the sponsor if the investigator becomes aware of them, following the procedures', 'described in Section 7.1.5.3.1.', 'At each contact with the patient, the investigator or designee must question the patient about', 'adverse events by asking an open-ended question such as, \"Have you had any unusual symptoms', 'or medical problems since the last visit? If yes, please describe.\" All reported or observed signs', 'and symptoms will be recorded individually, except when considered manifestations of a', 'medical condition or disease state. A precise diagnosis will be recorded whenever possible.', 'When such a diagnosis is made, all related signs, symptoms, and any test findings will be', 'recorded collectively as a single diagnosis on the CRF and, if it is a serious adverse event, on the', 'Serious Adverse Event Form.', 'The clinical course of each adverse event will be monitored at suitable intervals until resolved,', 'stabilized, or returned to baseline; until the patient is referred for continued care to a health care', 'professional; or until a determination of a cause unrelated to the IMP or study procedure is made.', 'The onset and end dates, duration (in case of adverse event duration of less than 24 hours), action', 'taken regarding IMP, treatment administered, and outcome for each adverse event must be', 'recorded both on the source documentation and the CRF.', 'The relationship of each adverse event to IMP and study procedures, and the severity and', 'seriousness of each adverse event, as judged by the investigator, must be recorded as described', 'below.', 'Further details are given in the safety monitoring plan.', '7.1.3.', 'Severity of an Adverse Event', 'The severity of each adverse event must be recorded as 1 of the following:', 'Mild:', 'No limitation of usual activities', 'Moderate: Some limitation of usual activities', 'Severe:', 'Inability to carry out usual activities', '80']\n\n###\n\n", "completion": "END"}